Repare Therapeutics Inc.
7171 Frederick-Banting, Building 2
Suite 270 St-Laurent
Montréal, QC H4S 1Z9
Canada
857 412 7018
https://www.reparerx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 179
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Lloyd Mitchell Segal | President, CEO & Director | 932.18k | 無 | 1964 |
| Mr. Steve Forte | Executive VP & CFO | 632k | 無 | 1979 |
| Dr. Maria Koehler M.D., Ph.D. | Executive VP & Chief Medical Officer | 693.28k | 無 | 1957 |
| Dr. Daniel Durocher Ph.D. | Co-Founder | 無 | 無 | 無 |
| Dr. Frank Sicheri Ph.D. | Co-Founder | 無 | 無 | 無 |
| Dr. Agnel Sfeir Ph.D. | Co-Founder | 無 | 無 | 無 |
| Dr. Michael Zinda Ph.D. | Executive VP & Chief Scientific Officer | 641.53k | 無 | 1971 |
| Mr. Daniel Belanger | Executive Vice President of Human Resource | 無 | 無 | 無 |
| Mr. Cameron Black | Executive Vice President of Discovery | 無 | 無 | 無 |
| Dr. Kim A. Seth Ph.D. | Executive VP & Chief Business Officer | 無 | 無 | 無 |
描述
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
公司管治
截至 無 止，Repare Therapeutics Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
